据知情人士透露，默克公司（Merck）已不再洽谈收购生物技术公司Revolution Medicines。

　　默克最近一直在洽谈收购RevMed，这笔交易对这家抗癌药生物技术公司的估值本可能在300亿美元左右。

　　一些知情人士说，在双方未能就价格达成一致后，谈判随之降温。

　　谈判总是有可能重启，或者RevMed可能会出现另一个求购方。RevMed预计将在今年上半年发布其胰腺癌和结直肠癌候选药物备受关注的测试数据。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：王永生

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.